PMV Pharmaceuticals Inc (PMVP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.29+4.03%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PMVP
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
PMVP — debt issuance
Dated 2026-09-01
Entry into a Material Definitive Agreement. On August 31, 2026, PMV Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC (the “Underwriter”), relating to an underwritten offering (the “Offering”) of (i) (a) 22,055,000 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”) and in lieu of Common Stock to certain investors, (b) pre-funded warrants to purchase an agg…
Why it matters: Good results could show that rezatapopt works well. This would help its market chance.
Supportive ifUpdated Phase 2 results show an overall response rate above 44% in the trial.
Worry ifResults show a response rate below 44% or no confirmed responses.
Why it matters: Managing expenses is crucial for PMV's financial health. Progress here can boost investor confidence.
Supportive ifOperating expenses decline by more than 10% in the next quarter.
Worry ifOperating costs go up or do not get better in the next quarter.
Why it matters: Finishing enrollment helps the trial move forward. Good data can increase investor trust.
Supportive ifThe PYNNACLE trial has good results. This is before the NDA is sent.
Worry ifEnrollment problems or bad trial results come out before the NDA is submitted.
Why it matters: Data from this trial could show if rezatapopt works well. This could help growth.
Supportive ifThe PYNNACLE trial shows good results. It shows strong effectiveness.
Worry ifThe trial results are not good. They show no strong effectiveness.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$241 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $701 loss on $10,000 · 7.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,167 loss on $10,000 · 41.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: More FDA designations can boost rezatapopt's market potential. They can also speed up its development.
Supportive ifPMV receives another FDA designation for rezatapopt. This could be Fast Track or Breakthrough Therapy.
Worry ifNo new FDA designations are given for rezatapopt in the next six months.
Why it matters: Missing earnings could show ongoing money problems. This may change how investors feel.
Worry ifFuture earnings report confirms a net loss similar to the recent quarter.
Less concerning ifThe earnings report shows a net profit or a much smaller loss.
Why it matters: Controlling cash burn is key to keeping operations running until rezatapopt may get approved. High burn rates can cause funding worries.
Worry ifNet cash used in operations decreases below $30 million in the next quarter.
Less concerning ifNet cash used in operations increases above $35 million in the next quarter.
Why it matters: New data may show the drug works well and is safe. This can change how investors feel and how the market sees it.
Supportive ifA new study shows good results for rezatapopt in treating TP53 Y220C tumors.
Worry ifNew data shows rezatapopt does not work well. It also has safety issues.
Why it matters: Higher cash burn could signal financial strain. It may impact PMV Pharma's ability to fund operations.
Worry ifNet cash used in operations remains below $34 million for the year.
Less concerning ifNet cash used in operations exceeds $34 million.
Why it matters: The earnings report will show if PMV continues to improve its financial performance.
Watch forEarnings were better than expected. This shows stronger financial health.
Also watch forEarnings were lower than expected. This shows ongoing money problems.
Why it matters: Watching cash burn is key for checking financial health and operation time.
Worry ifCash burn rate drops a lot compared to past quarters.
Less concerning ifCash burn rate goes up or stays high. This risks financial stability.
Why it matters: This submission is key for PMV Pharma's growth. It could lead to accelerated approval for a new treatment.
Supportive ifThe NDA is submitted as planned in Q1 2027 for rezatapopt.
Worry ifThe NDA submission is delayed or not filed in Q1 2027.